Sartorius Stedim Biotech strengthens product portfolio for cell and gene therapies by acquiring a majority stake in CellGenix
- Friday, July 2, 2021, 7:14
- PR Newswire
- Add a comment
AUBAGNE, France, July 2, 2021 /PRNewswire/ — Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, and with a sales subsidiary near the…
About the Author
admin has written 20720 stories on this site.